Shandong Sito Bio-technology Co Ltd - Asset Resilience Ratio

Latest as of September 2020: 0.35%

Shandong Sito Bio-technology Co Ltd (300583) has an Asset Resilience Ratio of 0.35% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Shandong Sito Bio-technology Co Ltd assets under control for the complete picture of this company's asset base.

Liquid Assets

CN¥10.00 Million
≈ $1.46 Million USD Cash + Short-term Investments

Total Assets

CN¥2.87 Billion
≈ $419.27 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2019)

This chart shows how Shandong Sito Bio-technology Co Ltd's Asset Resilience Ratio has changed over time. See 300583 equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Shandong Sito Bio-technology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Shandong Sito Bio-technology Co Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥10.00 Million 0.35%
Total Liquid Assets CN¥10.00 Million 0.35%

Asset Resilience Insights

  • Limited Liquidity: Shandong Sito Bio-technology Co Ltd maintains only 0.35% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shandong Sito Bio-technology Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shandong Sito Bio-technology Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Royalty Pharma Plc
NASDAQ:RPRX
Biotechnology 0.11%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 65.12%
Hyundai Bioscience Co. Ltd
KQ:048410
Biotechnology 13.57%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 82.25%
Lifecome Biochemistry Co Ltd
SHE:002868
Biotechnology 4.69%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%

Annual Asset Resilience Ratio for Shandong Sito Bio-technology Co Ltd (2017–2019)

The table below shows the annual Asset Resilience Ratio data for Shandong Sito Bio-technology Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2019-12-31 6.81% CN¥203.36 Million
≈ $29.76 Million
CN¥2.99 Billion
≈ $437.13 Million
-14.84pp
2018-12-31 21.64% CN¥561.57 Million
≈ $82.18 Million
CN¥2.59 Billion
≈ $379.65 Million
-5.96pp
2017-12-31 27.61% CN¥558.88 Million
≈ $81.78 Million
CN¥2.02 Billion
≈ $296.26 Million
--
pp = percentage points

About Shandong Sito Bio-technology Co Ltd

SHE:300583 China Biotechnology
Market Cap
$363.65 Million
CN¥2.49 Billion CNY
Market Cap Rank
#14125 Global
#4320 in China
Share Price
CN¥13.10
Change (1 day)
-2.96%
52-Week Range
CN¥12.93 - CN¥19.15
All Time High
CN¥50.68
About

Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a me… Read more